Cost-effectiveness of atypical antipsychotics in chronic schizophrenia

Abstract

It is nearly a decade since the first atypical antipsychotic, clozapine, was launched in the UK. There are now several other similar drugs on the market. They are all more expensive than traditional antipsychotics and the question of whether they are a cost-effective use of scare NHS resources is an important one. This article reviews the evidence in the area of treatment-resistant schizophrenia.